Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Metabolic dysfunction-associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy

  • Cardoso Delgado, Teresa de Jesús
  • Martín-Cuevas, Celia
  • Sánchez-Hidalgo, Ana C.
  • Gil-Gómez, Antonio
  • Rejano-Gordillo, Claudia María
  • Landa, Jon
  • Gallego-Durán, Rocío
  • Goikoetxea-Usandizaga, Naroa
  • González-Recio, Irene
  • Gil-Pitarch, Clàudia
  • Zapata-Pavas, L. Estefanía
  • Barrenechea-Barrenechea, Jon Ander
  • Conter, Carolina
  • Martínez-Cruz, Luis Alfonso
  • Ramos Herrero, Víctor
  • Nogueiras, Rubén
  • Azkargorta, Mikel
  • Elortza, Félix
  • Moncho-Amor, Verónica
  • Crespo, Javier
  • Matheu, Ander
  • Romero-Gómez, Manuel
  • Crespo-Facorro, Benedicto
  • Martínez-Chantar, María Luz
[Data and materials availability:] The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE [1] partner repository with the dataset identifier PXD063321 (www.ebi.ac.uk/pride/archive/projects/PXD063321). All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials., Metabolic dysfunction–associated steatotic liver disease (MASLD), a liver-centric condition, is associated with cognitive impairment and sensorimotor alterations. However, it remains unclear whether MASLD is sufficient to drive central nervous system deficits. Here, using diet-induced mouse models, we showed that MASLD was associated with alterations in social memory, sensorimotor processing, and hippocampal function, including decreased parvalbumin-positive interneurons, reduced dendritic spine density, and diminished dentate gyrus neurogenesis and neuronal differentiation. Then, we selectively modulated liver metabolism through N-acetylgalactosamine small interfering RNA (siRNA) therapy against Cyclin M4 (CNNM4), a magnesium transporter dysregulated in MASLD. Liver-specific intervention with siRNA-Cnnm4 reversed impaired social memory and sensorimotor processing in association with recovery of hippocampal synaptogenesis and mitochondrial function pathways, alongside activation of neurogenesis-associated transcriptional programs. Our findings demonstrate that liver pathology is sufficient to drive neurobehavioral and hippocampal dysfunction in MASLD. Hepatic-specific intervention restores brain function, strongly supporting the existence of a causal and therapeutically targetable liver-brain axis for MASLD-associated neurological complications., This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: CEX2021-001136-S (to M.L.M.-C.) and MICINN: PID2022-139395OB-100 (to M.L.M.-C.); integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER; and Project funded by CIBEREHD; 2018 BBVA Foundation Grants for Scientific Research Teams- UMBRELLA (to M.L.M.-C., M.R.G., and B.C.-F.). T.C.D. is funded by “Ayuda RYC2020-029316-I financiada por MCIN/AEI/10.13039/501100011033 y por El FSE invierte en tu futuro.” This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116OB-I00 (to T.C.D.). C.M.-C. was supported by CIBERSAM (G26) and the Instituto de Salud Carlos III (AC23_2/00034). A.C.S.H. received funding from CIBERSAM (G26) and the Consejería de Salud y Familias (RH-0063). V.D.R.H. was supported by the Agencia Estatal de Investigación (PID2019-109405R and PI-0014-2022). L.E.Z.-P. was supported by a PhD fellowship from the Provincial Section of Bizkaia from the Scientific Foundation of the Spanish Association Against Cancer PRDVZ233980ZAPA. C.M.R.G. was supported by Ayuda Juan de la Cierva JDC2023-052761-I from the MCIN/AEI/10.13039/501100011033–Unión Europea NextGenerationEU/PRTR. V.M.-A. was supported by the Miguel Servet contract (CP23/00111) from the ISCIII. This project has also received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 (agreement no. 101095679), Spanish Instituto de Salud Carlos III-FEDER Grant (FIS-PI22/01853) and European Union-NextGenerationEU (PMP21/00112) (to J.C.)., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed